Soluble urokinase plasminogen activator receptor (suPAR) is a novel, independent predictive marker of myocardial infarction in HIV-1-infected patients: a nested case-control study.
about
Contribution of Hepatitis B to Long-Term Outcome Among Patients With Acute Myocardial Infarction: A Nationwide Study.Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study.Risk of Cardiovascular Disease in an Aging HIV Population: Where Are We Now?Low-dose growth hormone therapy reduces inflammation in HIV-infected patients: a randomized placebo-controlled study.Serum suPAR and syndecan-4 levels predict severity of community-acquired pneumonia: a prospective, multi-centre study.The intriguing role of soluble urokinase receptor in inflammatory diseases.
P2860
Soluble urokinase plasminogen activator receptor (suPAR) is a novel, independent predictive marker of myocardial infarction in HIV-1-infected patients: a nested case-control study.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 September 2015
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Soluble urokinase plasminogen ...... : a nested case-control study.
@en
Soluble urokinase plasminogen ...... : a nested case-control study.
@nl
type
label
Soluble urokinase plasminogen ...... : a nested case-control study.
@en
Soluble urokinase plasminogen ...... : a nested case-control study.
@nl
prefLabel
Soluble urokinase plasminogen ...... : a nested case-control study.
@en
Soluble urokinase plasminogen ...... : a nested case-control study.
@nl
P2093
P2860
P50
P356
P1433
P1476
Soluble urokinase plasminogen ...... s: a nested case-control study
@en
P2093
G Kronborg
J Gerstoft
T L Katzenstein
P2860
P304
P356
10.1111/HIV.12315
P50
P577
2015-09-14T00:00:00Z